Meta-analysis with individual data of functional outcomes following Aquablation for lower urinary tract symptoms due to BPH in various prostate anatomies
BMJ Surgery, Interventions, & Health Technologies · 2021-06 · 3 (1) · e000090
DOI: 10.1136/bmjsit-2021-000090 ↗Kurz gefasst
Metaanalyse in der Zeitschrift BMJ Surgery, Interventions, & Health Technologies, online erschienen am 24.06.2021. Verfasst von Dean Elterman und 11 weiteren Autor:innen. Beteiligte Einrichtung: Surgery, University of Toronto, Toronto, Ontario, Canada. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objectives
To evaluate functional outcomes following Aquablation in various prostate volume and anatomical subgroups.
Design
A meta-analysis with individual patient data undergoing Aquablation therapy from four prospective, global, clinical studies that have been conducted with Aquablation; WATER, WATER II, FRANCAIS WATER and OPEN WATER.
Setting
Australia, Canada, Lebanon, Germany, New Zealand, UK and the USA.
Participants
425 men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) with 1-year follow-up.
Interventions
Aquablation therapy is an ultrasound guided, robotically executed waterjet ablative procedure for the prostate. Main outcome measures The analyses focus International Prostate Symptom Score (IPSS), uroflowmetry, postoperative Incontinence Severity Index (ISI) and surgical retreatment.
Results
425 men with prostates ranging in size from 20 to 150 mL underwent Aquablation therapy. The outcomes from the seven questions in the IPSS questionnaire were grouped by the following; prostates 4, and regardless of prostate size, showed a reduction in incontinence during patient follow-up. Surgical retreatment due to BPH symptoms occurred in 0.7% (95% CI 0.1%–2.0%).
Conclusions
Across a variety of prostate anatomies, Aquablation therapy showed remarkable functional improvements following the index procedure. Additionally, men with moderate to severe LUTS/BPH and overactive bladder resulting in urge incontinence showed a reduction in incontinence symptoms postprocedure.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Surgery, University of Toronto, Toronto, Ontario, Canada.
- Urology, Tauranga Hospital, Tauranga, New Zealand.
- Urology, The University of Texas Southwestern Medical Center, Dallas, Texas, USA.
- Urology, Frimley Health NHS Foundation Trust, Frimley, Surrey, UK.
- Urology, Clinique Pasteur, Toulouse, France.
- University of Montreal Hospital Center, Universite de Montreal, Montreal, Québec, Canada.
ORCID-Profile: Dean Elterman, Vincent Misrai
Zitieren
APA
Elterman, D., Gilling, P., Roehrborn, C., Barber, N., Misrai, V., Zorn, K. C., Bhojani, N., Te, A., Humphreys, M., Kaplan, S., Desai, M., & Bach, T. (2021). Meta-analysis with individual data of functional outcomes following Aquablation for lower urinary tract symptoms due to BPH in various prostate anatomies. BMJ Surgery, Interventions, & Health Technologies, 3(1), e000090. https://doi.org/10.1136/bmjsit-2021-000090
Vancouver
Elterman D, Gilling P, Roehrborn C, Barber N, Misrai V, Zorn KC, et al. Meta-analysis with individual data of functional outcomes following Aquablation for lower urinary tract symptoms due to BPH in various prostate anatomies. BMJ Surgery, Interventions, & Health Technologies. 2021;3(1):e000090. doi:10.1136/bmjsit-2021-000090
BibTeX
@article{Elterman2021,
author = {Elterman, Dean and Gilling, Peter and Roehrborn, Claus and Barber, Neil and Misrai, Vincent and Zorn, Kevin C and Bhojani, Naeem and Te, Alexis and Humphreys, Mitch and Kaplan, Steven and Desai, Mihir and Bach, Thorsten},
title = {Meta-analysis with individual data of functional outcomes following Aquablation for lower urinary tract symptoms due to BPH in various prostate anatomies},
journal = {BMJ Surgery, Interventions, & Health Technologies},
year = {2021},
volume = {3},
number = {1},
pages = {e000090},
doi = {10.1136/bmjsit-2021-000090}
}
EUVIMED